Clinical trial
A Randomised, Single-blind, Placebo-controlled, Phase 1, Single-ascending and Multiple-dose Study in Adult Subjects With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124.
NCT04718844 is registered in ClinicalTrials.gov with Silence Therapeutics plc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Single-blind, Placebo-controlled, Phase 1, Single-ascending and Multiple-dose Study in Adult Subjects With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124.
- Lead sponsor
- Silence Therapeutics plc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 14, 2021
- Completion date
- May 23, 2023
- Enrollment
- 44 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.
low risk myelodysplastic syndrome, non-transfusion-dependent thalassemia, very-low risk myelodysplastic syndrome